Lacosamide is Associated with a Higher Treatment Persistence at 12 Months than Brivaracetam and Perampanel Despite Similar Efficacy Article Swipe
Related Concepts
No concepts available.
Roberta Roberti
,
Francesca Anzellotti
,
Vincenzo Belcastro
,
Simone Beretta
,
Giovanni Boero
,
Paolo Bonanni
,
Laura Canafoglia
,
Carmen De
,
Roberta Di Giacomo
,
Jacopo C. DiFrancesco
,
Fedele Dono
,
Giovanni Falcicchio
,
Antonio Gambardella
,
Alfonso Giordano
,
Angelo Labate
,
Simona Lattanzi
,
Claudio Liguori
,
Pietro Mattioli
,
Annacarmen Nilo
,
Francesca Felicia Operto
,
Angelo Pascarella
,
Giada Pauletto
,
Luciano Antonio Nassar Pellegrino
,
Rosaria Renna
,
Gionata Strigaro
,
Dario Arnaldi
,
Valeria Badioni
,
Chiara Bedetti
,
Roberto Cantello
,
Alberto Danieli
,
Giacomo Evangelista
,
Mariana Fernandes
,
Matilde Lazzari
,
Andrea Maialetti
,
Elisa Osanni
,
Maria Grazia Pascarella
,
Chiara Pastori
,
Stefano L. Sensi
,
Payam Tabaee Damavandi
,
Lorenzo Tinti
,
Lorenzo Verriello
,
Flavio Villani
,
Pio Zoleo
,
Emilio Russo
,
Gianfranco Di Gennaro
·
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1007/s40120-025-00860-5
· OA: W4416422199
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1007/s40120-025-00860-5
· OA: W4416422199
Treatment discontinuation in epilepsy emerges as a dynamic process shaped by both tolerability and clinical response. Early persistence was higher for LCM, whereas long-term retention was improved for BRV and PER. These results support a personalized approach to ASM selection that integrates early tolerability with sustained effectiveness.
Related Topics
Finding more related topics…